Format

Send to

Choose Destination
Epidemiol Infect. 2017 Jul;145(10):1962-1982. doi: 10.1017/S0950268817000747. Epub 2017 Apr 27.

Human papillomavirus 9-valent vaccine for cancer prevention: a systematic review of the available evidence.

Author information

1
Department of Medicine and Surgery,University of Parma,Parma,Italy.
2
European Institute of Oncology - Medical Office,Milan,Italy.
3
University of Liverpool,Liverpool,UK.
4
Giovanni Lorenzini Medical Science Foundation,Houston, TX,USA.
5
HPV-Unit,Regina Elena National Cancer Institute,Rome,Italy.
6
Centre for Economic and International Studies,University of Rome "Tor Vergata",Rome,Italy.
7
School of Medicine, University of Brescia,Brescia,Italy.
8
Department of Infectious Diseases,Istituto Superiore di Sanità,Rome,Italy.
9
Department of Paediatrics,University of Milan,Milan,Italy.

Abstract

In 2014, the Food and Drug Administration approved a new human papillomavirus 9-valent vaccine (9vHPV), targeting nine HPV types: HPV types 6, 11, 16, and 18, which are also targeted by the quadrivalent HPV vaccine (qHPV), plus five additional high cancer risk HPV types (HPV types 31, 33, 45, 52, and 58). The aim of the current study was to systematically retrieve, qualitatively and quantitatively pool, as well as critically appraise all available evidence on 9vHPV from randomized controlled trials (RCTs). We conducted a systematic review of the literature on 9vHPV efficacy, immunogenicity and safety, as well as a systematic search of registered, completed, and ongoing RCTs. We retrieved and screened 227 records for eligibility. A total of 10 publications reported on RCTs' results on 9vHPV and were included in the review. Sixteen RCTs on 9vHPV have been registered on RCT registries. There is evidence that 9vHPV generated a response to HPV types 6, 11, 16 and 18 that was non-inferior to qHPV. Vaccine efficacy against five additional HPV type-related diseases was directly assessed on females aged 16-26 years (risk reduction against high-grade cervical, vulvar or vaginal disease = 96·7%, 95% CI 80·9%-99·8%). Bridging efficacy was demonstrated for males and females aged 9-15 years and males aged 16-26 years (the lower bound of the 95% CIs of both the geometric mean titer ratio and difference in seroconversion rates meeting the criteria for non-inferiority for all HPV types). Overall, 9vHPV has been proved to be safe and well tolerated. Other RCTs addressed: 9vHPV co-administration with other vaccines, 9vHPV administration in subjects that previously received qHPV and 9vHPV efficacy in regimens containing fewer than three doses. The inclusion of additional HPV types in 9vHPV offers great potential to expand protection against HPV infection. However, the impact of 9vHPV on reducing the global burden of HPV-related disease will greatly depend on vaccine uptake, coverage, availability, and affordability.

KEYWORDS:

human papillomavirus 9-valent vaccine; Cancer prevention; HPV; systematic review

PMID:
28446260
PMCID:
PMC5974698
DOI:
10.1017/S0950268817000747
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Cambridge University Press Icon for PubMed Central
Loading ...
Support Center